5-苄基-4-(4-甲氧基苯基)噻唑-2-胺 | 106511-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-苄基-4-(4-甲氧基苯基)噻唑-2-胺
• 英文名称: 5-benzyl-4-(4-methoxyphenyl)thiazol-2-amine
• 英文别名: 5-benzyl-4-(4-methoxy-phenyl)-thiazol-2-ylamine；5-benzyl-4-(4-methoxyphenyl)-1,3-thiazol-2-amine
• CAS: 106511-73-3
• 化学式: C₁₇H₁₆N₂OS
• 分子量: 296.393
• InChiKey: JRHSRQVRQLHVCM-UHFFFAOYSA-N

物化性质

• 熔点：
  155-156 °C
• 沸点：
  503.1±50.0 °C(Predicted)
• 密度：
  1.219±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  76.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-苄基-4-(4-甲氧基苯基)噻唑-2-胺 在 lithium hydroxide monohydrate 、 亚硝酸异戊酯 作用下， 以 水 、 乙腈 为溶剂， 反应 15.33h， 生成 5-benzyl-N,N-diethyl-4-(4-methoxyphenyl)thiazol-2-amine
  参考文献：
  名称：

  2,4,5-Trisubstituted thiazole derivatives: A novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase

  摘要：

  Novel 2,4,5-trisubstituted thiazole derivatives (TSTs) were designed and synthesized as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Among the thirty-eight synthesized target compounds, thirty TSTs showed potent inhibition against HIV-1 replication in wild type HIV-1 at submicromolar concentrations (from 0.046 to 9.59 mu M). Compounds 21, 23 and 24 were also tested on seven NNRTI-resistant HIV-1 strains, and all exhibited inhibitory effects with fold changes in IC50 ranging from 2.6 to 111, which were better than those of nevirapine (15.6-fold-371-fold). Docking simulations of compound 24 revealed a reasonable mechanism for the binding mode, and three-dimensional quantitative structure activity relationship (3-DQSAR) studies on this novel series of TST further elucidated the structure-activity relationship (SAR). The results suggested the great potential of TSTs as a novel class of NNRTIs with antiviral efficacy and a good resistance profile. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.07.072
• 作为产物：
  描述：

  1-(4-甲氧基苯基)-3-苯基-丙-1-酮 在 溴 作用下， 以 四氯化碳 、 乙醇 为溶剂， 生成 5-苄基-4-(4-甲氧基苯基)噻唑-2-胺
  参考文献：
  名称：

  Ahluwalia, V. K.; Kaila, Neelu; Bala, Shashi, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1986, vol. 25, p. 502 - 504

  摘要：

  DOI：

文献信息

• TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF
  申请人：Li Song

  公开号：US20090298832A1

  公开（公告）日：2009-12-03

  The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.

  本发明涉及公式（I）的2,4,5-三取代噻唑化合物或所有可能的异构体、前药、药用盐、溶剂合物或水合物，用于抑制血浆PLTP活性和/或血浆CETP活性，其中取代基如规范中定义；一种用于制备公式（I）化合物的方法；包括公式（I）化合物的药物组合物以及其用于制备治疗和/或预防与哺乳动物体内增加的血浆PLTP活性和/或增加的血浆CETP活性相关的疾病的药物的用途，如动脉粥样硬化、心血管疾病和周围血管疾病等。
• Trisubstituted thiazole compounds, preparations methods, pharmaceutical compositions and medicals uses thereof
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.C. China

  公开号：US08053581B2

  公开（公告）日：2011-11-08

  The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.

  本发明涉及公式(I)的2,4,5-三取代噻唑化合物或其所有可能的异构体、前药、药学上可接受的盐、溶剂化合物或水合物，用于抑制血浆PLTP活性和/或血浆CETP活性，其中取代基如规范中所定义；一种制备公式(I)化合物的方法；包括公式(I)化合物的制药组合物以及其用于制备哺乳动物（如动脉粥样硬化、心血管疾病和周围血管疾病等）的治疗和/或预防与增加的血浆PLTP活性和/或增加的血浆CETP活性相关的疾病的药物的用途。
• 2,4,5-trisubstituted thiazole compounds,preparation methods,pharmaceutical compositions and medical uses thereof
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L. A. China

  公开号：EP2772488A1

  公开（公告）日：2014-09-03

  The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.

  本发明涉及用于抑制血浆PLTP活性和/或血浆CETP活性的式(I)的2,4,5-三取代噻唑化合物或其所有可能的异构体、原药、药学上可接受的盐、溶液或水合物，其中取代基如说明书中所定义；制备式(I)化合物的工艺；一种包含式（I）化合物的药物组合物及其用于制备治疗和/或预防与哺乳动物血浆 PLTP 活性升高和/或血浆 CETP 活性升高有关的疾病（如动脉粥样硬化、心血管疾病和外周血管疾病等）的药物。
• 2,4,5-TRISUBSTITUTED THIAZOLE COMPOUNDS,PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L. A. China

  公开号：EP2042494B1

  公开（公告）日：2014-07-09
• AHLUWALIA V. K.; KAILA NEELU; BALA SHASHI, INDIAN J. CHEM., 25,(1986) N 5, 502-504
  作者：AHLUWALIA V. K.、 KAILA NEELU、 BALA SHASHI

  DOI：——

  日期：——